Contact Information: Company Contact: Edward C. Larkin Chief Operating Officer 303-867-3415
Omni Bio Pharmaceutical to Present at Accredited Members Fall 2009 Micro Cap / Small Cap Investment Conference
| Source: Omni Bio Pharmaceutical
DENVER, CO--(Marketwire - September 22, 2009) - Omni Bio Pharmaceutical, Inc. (OTCBB : OMBP )
today announced that its executive management team will present at the
Accredited Members Fall 2009 Micro Cap / Small Cap Investment Conference,
which is being held at the Broadmoor Hotel Resort in Colorado Springs, CO,
on September 28-29, 2009. Presenting on behalf of Omni Bio are Dr. Charles
Dinarello, acting chief executive officer; Dr. Leland Shapiro, principal
scientific investigator; and Edward Larkin, chief operating officer. The
Company's presentation, which is scheduled for 3:30 p.m. MT on September
28, 2009, will include an update on current company developments. A copy
of the slides used in the presentation will be filed with the Securities
and Exchange Commission as an exhibit to a Form 8-K prior to the
presentation.
About Omni Bio Pharmaceutical, Inc.
Omni is the licensee of issued and pending patents from the University of
Colorado Denver. Omni has been advancing broad-spectrum therapeutics
targeting bacterial and viral diseases, biohazards, diabetes, and
transplant rejection since February 2006. The Company's core technology is
based on novel discoveries made at the University of Colorado involving
therapeutic agents already approved for use in humans.
Safe Harbor Statement
Certain statements in this press release and in the referenced presentation
are forward-looking statements as defined in the Private Securities
Litigation Reform Act of 1995. We use words such as "anticipate,"
"believe," "could," "should," "estimate," "expect," "intend," "may,"
"predict," "project," "target," and similar terms and phrases, including
references to assumptions, to identify forward-looking statements. The
forward-looking statements in this press release and in the presentation
are based on information available to us as of the date any such statements
are made and we assume no obligation to update these forward-looking
statements. These statements are subject to risks and uncertainties that
could cause actual results to differ materially from those described in the
statements. These risks and uncertainties include, but are not limited to,
the following: our lack of revenue, our operating losses, our need for
additional funding to continue operations, our ability to successfully
commercialize our products, our limited experience in developing and
commercializing products, the uncertainty and expense of clinical trials,
our ability to adequately protect our intellectual property, the
uncertainty and expense of government regulations, our limited product
marketing capabilities and other risk factors described from time to time
in our reports filed with the Securities and Exchange Commission, including
our most recent annual report on Form 10-K and subsequent quarterly reports
on Form 10-Q all of which are available at www.sec.gov.